Table 3 Patients achieving MCIDs for each PRO at week 12
Methotrexate add-on study | Monotherapy study (all q.d. doses) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Placebo (N = 86) | 50 mg q.d. (N = 82) | 100 mg q.d. (N = 85) | 200 mg q.d. (N = 86) | 25 mg b.i.d. (N = 86) | 50 mg b.i.d. (N = 85) | 100 mg b.i.d. (N = 84) | Placebo (N = 72) | 50 mg (N = 72) | 100 mg (N = 70) | 200 mg (N = 69) | |
HAQ-DI, n (%) | 49 (57) | 60 (73) | 64 (75) | 74 (86) | 61 (71) | 57 (67) | 70 (83) | 37 (52) | 51 (73) | 55 (79) | 55 (80) |
Patient Global, n (%) | 52 (61) | 56 (68) | 60 (71) | 67 (78) | 58 (67) | 62 (73) | 65 (77) | 35 (49) | 56 (78) | 50 (71) | 52 (75) |
Patient Pain, n (%) | 50 (58) | 54 (66) | 55 (66) | 66 (77) | 59 (69) | 58 (68) | 67 (80) | 39 (55) | 54 (77) | 51 (73) | 56 (81) |
FACIT-Fatigue scale, n (%) | 51 (59) | 47 (57) | 60 (71) | 64 (74) | 54 (63) | 55 (65) | 59 (71) | 32 (45) | 48 (69) | 52 (74) | 51 (74) |
SF-36 PCS, n (%) | 43 (50) | 55 (67) | 60 (71) | 68 (79) | 58 (67) | 62 (73) | 66 (80) | 30 (42) | 48 (69) | 49 (70) | 54 (78) |
SF-36 MCS, n (%) | 49 (57) | 44 (54) | 48 (57) | 64 (74) | 43 (50) | 38 (45) | 53 (64) | 34 (48) | 39 (56) | 52 (74) | 46 (67) |